WO2002036592A1 - Remedes aux maladies causees par l'acide arachidonique - Google Patents
Remedes aux maladies causees par l'acide arachidonique Download PDFInfo
- Publication number
- WO2002036592A1 WO2002036592A1 PCT/JP2001/009575 JP0109575W WO0236592A1 WO 2002036592 A1 WO2002036592 A1 WO 2002036592A1 JP 0109575 W JP0109575 W JP 0109575W WO 0236592 A1 WO0236592 A1 WO 0236592A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arachidonic acid
- acid
- skin diseases
- cell carcinoma
- skin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a therapeutic agent for skin diseases. More specifically, the present invention relates to a preventive or therapeutic agent for a skin disease caused by an increase in arachidonic acid metabolism, such as psoriasis, ultraviolet dermatitis, hypertrophy, basal cell carcinoma or stabular cell carcinoma.
- arachidonic acid metabolism such as psoriasis, ultraviolet dermatitis, hypertrophy, basal cell carcinoma or stabular cell carcinoma.
- Prostaglandins (PGs) and leucos (LTs) produced by acid metabolic pathways are involved in the regulation of physiological functions such as gastric acid secretion, platelet aggregation, and various smooth muscle contractions, and are fatty acids that cause tissue inflammation.
- Communicator (mediator) PG and LT are important for the maintenance of homeostasis in the body, but overproduction of some dermatological diseases is considered to be the main cause of the disease.
- Psoriasis is a chronic disease that shows benign abnormal proliferation of epidermal cells and infiltration of polymorphonuclear leukocytes into the epidermis, and is closely related to abnormalities of arachidonic acid metabolites for the following reasons (1) to (4). It is considered a disease.
- (1) PG, arachidonic acid and 12-HETE increase in psoriatic rash
- LTB 4 Leukotriene 5,12-dihydroxy form
- Representative examples of skin diseases caused by abnormal arachidonic acid metabolism include the following diseases.
- Mastocytosis This is a condition in which histamine and other substances are released from mast cells grown on the skin, causing flushing of the skin and junctional measles. Although these symptoms are considered to be mainly due to histamine, antihistamines are used.However, histamine-resistant cases in which PG synthesis inhibitors are significantly improved are seen (Main, RA et al. Br. . J.
- Sunlight dermatitis It is thought that inflammatory mediators such as PG cause vasodilation by medium wavelength ultraviolet light.
- Basal cell carcinoma or stab cell carcinoma (all skin cancers): PG is increased, and it has been suggested that PG is involved in the growth of the tumor (Vanderveen, ⁇ ., . ⁇ ⁇ et al.
- Antiviral activity Antiviral activity in a herpesvirus (Tomai. MA. Et al. Antiviral Res. 28, 253-264 (1995)) infection system has been reported.
- Cytokine 9883-845 (1997)), which is not found in imiquimod but found only in R848, is due to the skin inflammation-inducing action of TNF_a; (Kondo, S et al. Eur Combined with J. Immunol. 27, 1713-8 (1997), it suggests that R848 may induce skin inflammation.
- An object of the present invention is to provide a novel skin disease therapeutic agent for treating and Z or preventing a skin disease caused by enhanced arachidonic acid metabolism, that is, a skin disease caused by increased production of PG, LT and the like. .
- the present inventors have already found the inhibitory effect of imiquimod on arachidonic acid-induced mouse ear edema, and have filed a patent application for the invention of a therapeutic agent for skin diseases such as psoriasis (Japanese Patent Application Laid-Open No. 2000-247884, supra).
- Rimi848 an analog of imiquimod, exhibits an extremely strong and persistent inhibitory action on arachidonic acid-induced mouse ear edema, and thus completed the present invention. That is, the gist of the present invention is represented by the following [1] to [6].
- R848 (4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1 ⁇ -imidazo [4,5-c] quinolin-1-ethanol, hereinafter abbreviated as R848) or an acid addition salt or solvate thereof
- R848 4-amino-2-ethoxymethyl- ⁇ , ⁇ -dimethyl-1 ⁇ -imidazo [4,5-c] quinolin-1-ethanol, hereinafter abbreviated as R848) or an acid addition salt or solvate thereof
- skin disease caused by an increase in arachidonic acid metabolism means a skin disease caused by an abnormal increase in arachidonic acid and its metabolites constituting an arachidonic acid metabolic pathway (arachidonic acid cascade).
- Typical disease names include psoriasis, UV dermatitis, mastocytosis, basal cell carcinoma or barbed cell carcinoma.
- Arachidonic acid metabolites are: (1) Prostaglandins produced by cyclooxygenase enzymes: PGE (prostaglandin E), PGF, PGI, TXA (thrompoxane A), etc., (2) lipoxygenase enzymes Leukotrienes produced by: LTB4, LTC, LTD, LTE, etc., and (3) 12-HETE etc., and inflammatory skin diseases resulting from abnormal increase of these mediators are described in the present invention. Applicable.
- the skin disease according to the present invention is caused by a virus or bacterial infection, skin inflammation due to burn injury or trauma, skin disease associated with collagen disease (autoimmune disease such as systemic lupus erythematosus, scleroderma), or a heterogeneous immune reaction. Does not include allergic skin diseases (junction, contact dermatitis, atopic dermatitis, etc.).
- autoimmune disease such as systemic lupus erythematosus, scleroderma
- a heterogeneous immune reaction Does not include allergic skin diseases (junction, contact dermatitis, atopic dermatitis, etc.).
- the active ingredient of the present invention can be easily synthesized according to a known method.
- a method described in W098 / 17279 may be used.
- the acid of the acid addition salt of R848 is not particularly limited as long as it is a pharmacologically acceptable acid, and may be a solvate such as a hydrate.
- Acid addition salts include inorganic acids (eg, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid), acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid It is formed with organic acids such as arginic acid, polydalminic acid, naphthylene sulfonic acid, naphthalenedisulfonic acid and polygalacturonic acid. Hydrochloric acid, sulfuric acid, acetic acid, oxalic acid, ascorbic acid and the like are suitable acid addition salts.
- R848 and its salts can take various formulation forms (eg, liquids, solids, capsules, etc.).
- Dosage forms for oral administration include, for example, tablets, capsules, pills, granules, powders, solutions, suspensions, and the like.
- Dosage forms for parenteral administration include, for example, injections Aqueous or oily agents, ointments, creams, lotions, aerosols, suppositories, patches and the like can be mentioned.
- the active ingredient can be incorporated with excipients and used in solutions, powders, powders, tablets, troches or capsules.
- Pharmaceutically compatible binding agents, and Z or adjuvant materials can be included as part of the composition.
- Tablets, pills, capsules and troches and the like can contain any of the following ingredients or compounds which are similar in nature: binder such as microcrystalline cellulose, gum tragacanth or gelatin; starch or lactate.
- Excipients such as glucose; dispersing agents such as alginic acid, rimogel or corn starch; magnesium stearate or Are lubricants such as Sterotes; lubricants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or, such as peppermint, methyl salicylate or orange flavor. Flavoring agent.
- the dosage unit form When the dosage unit form is forceps, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
- dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac or enteric agents.
- R848 and a pharmaceutically acceptable salt can be administered as an ingredient such as an elixir, suspension, syrup, wafer, or gum.
- a syrup may contain, in addition to the active ingredients, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- R8488 can also be prepared as a sustained release formulation including implants and microcapsule administration systems.
- a biodegradable and biocompatible polymer such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, silicon, polyorthoester and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art, and the materials are also commercially available.
- a ribosome suspension can be prepared by a method known to those skilled in the art using an appropriate lipid (eg, stearoyl phosphatidylethanolamine, stearate roll) as a carrier.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous or topical applications containing R848 as an active ingredient can include the following ingredients.
- Sterile diluents such as water for injection, saline solution, fixed oils, fixed oils, polyethylene glycols, glycerin, propylene dalycol or other synthetic solvents; fungicides such as benzyl alcohol or methyl paraben; ascorbic acid or sulfite Antioxidants such as sodium hydrogen; chelating agents such as ethylenediaminetetraacetic acid; acetate, citrate Or buffers such as phosphate and agents for adjusting tonicity such as sodium chloride or dextrose.
- Parenteral preparations may be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- Injectables can be prepared in a conventional manner, for example, by dissolving the compound in an appropriate solvent (eg, sterilized water, buffer, physiological saline, etc.), and then sterilizing by filtering through a filter or the like. Then, it can be prepared by filling in a sterile container.
- the preferred carriers are saline or phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- an external preparation is one of particularly suitable dosage forms.
- R 848 is imiquimod with approximate chemical structure, 1- (2-methylpropyl)-1H-imidazo [4,5-c] quinoline-4- at least 20 times more water-soluble than quinoline-4-amine (Water solubility at pH 2.5, 5.5, and 7: 1000 ⁇ /] 111 or more). Due to this property, the medicament of the present invention is not only easy to formulate, but also has a low transferability of the active ingredient to the central and other tissues. The effect on the affected area is durable. As described above, the R848-containing preparation of the present invention has particularly excellent properties as an external preparation.
- the form of the external preparation is not particularly limited, and may be in the form of cream, paste, jelly, gel, emulsion, liquid, etc.
- any pharmaceutically acceptable base may be used, and conventionally known bases such as ointments, liniments, lotions and the like can be used.
- polyvinyl alcohol sodium polyacrylate, methoxyethylene-polymers such as maleic anhydride copolymer, poly
- inorganic fillers such as kaolin, bentonite, zinc oxide, and titanium oxide; viscosity regulators; antioxidants; PH regulators; humectants such as glycerin and propylene glycol may be added. .
- external bases In the case of external bases (ointments, creams, etc.), generally 1 to 100 mg, preferably 3 to 300 mg, of R8488 or a salt thereof is contained as an active ingredient per 1 g of plaster. Can be.
- the dosage form and dosage of the medicament of the present invention are not particularly limited, and may be any method that can be used by a person skilled in the art as appropriate.
- oral administration in the case of oral administration, it can be administered in the form of inhalants or capsules, tablets, granules, etc.
- inhalants or capsules, tablets, granules, etc. in the range of about 1 to about 100 mg / day for adults for adults It is preferably administered in the range of about 10 to about 50 mg in one or several doses.
- parenteral administration it can be used in the form of subcutaneous or intravenous injections, drops, or ointments in an aqueous suspension.
- the dose varies depending on the patient's condition, age, weight, etc., and the dose used will be appropriately large enough to effectively treat the target disease.
- a range of 100 mg, preferably about 3 to about 100 mg, can be administered in one or several divided doses.
- topical transdermal preparations solutions, oily ointments, hydrophilic ointments or creams
- the amount used depends on the type and condition of the disease.
- the amount of external preparation should be 0.1 to 100 g, more preferably 1 to 10 g per day, applied once or at appropriate times to the affected area. Good. Industrial applicability
- various skin diseases caused by abnormal arachidonic acid metabolism can be treated safely and effectively.
- arachidonic acid metabolism such as psoriasis, ultraviolet dermatitis, mastocytosis, basal cell tumor, and barbed cell carcinoma
- BALB / c mice female, 6 weeks old were purchased from Charles River Japan (Kanagawa, Japan) and preliminarily reared and used until 8 weeks old.
- R848 (2 mg / mK 20 mg / ml) showed a significant inhibitory effect on arachidonic acid-induced intradermal reaction even after 4 hours from application. This result indicates that the preparation containing R848 is effective as a therapeutic or prophylactic agent for skin diseases caused by increased arachidonic acid metabolism.
- Table 2 Water solubility of R848 and imiquimod in the acidic to neutral range
Abstract
L'invention concerne des médicaments servant à prévenir et/ou à traiter des maladies de la peau causées par l'acide arachidonique, et contenant comme principe actif 4-amino-2-éthoxyméthyl-α,α-diméthyl-1H-imidazo[4,5-c]quinoline-1-éthanol:R848 ou son sel ou solvat d'ddition acide. L'utilisation de ces médicaments permet de traiter de manière sûre et efficace diverses maladies de la peau causées par le métabolisme accéléré de l'acide ararchidonique (psoriasis, dermatite réagissant aux ultra-violets, mastocytome, basilome, carcinome cellulaire squameux, etc.).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002212695A AU2002212695A1 (en) | 2000-11-06 | 2001-10-31 | Remedies for arachidonic acid-induced skin diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000337359A JP2002145777A (ja) | 2000-11-06 | 2000-11-06 | アラキドン酸誘発皮膚疾患治療剤 |
JP2000-337359 | 2000-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002036592A1 true WO2002036592A1 (fr) | 2002-05-10 |
Family
ID=18812759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/009575 WO2002036592A1 (fr) | 2000-11-06 | 2001-10-31 | Remedes aux maladies causees par l'acide arachidonique |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2002145777A (fr) |
AU (1) | AU2002212695A1 (fr) |
WO (1) | WO2002036592A1 (fr) |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6534654B2 (en) | 1996-06-21 | 2003-03-18 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6699878B2 (en) | 1997-12-11 | 2004-03-02 | 3M Innovative Properties Company | Imidazonaphthyridines |
US6780873B2 (en) | 1999-06-10 | 2004-08-24 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6784188B2 (en) | 1999-06-10 | 2004-08-31 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6797718B2 (en) | 2002-06-07 | 2004-09-28 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US6818650B2 (en) | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
US6825350B2 (en) | 1999-06-10 | 2004-11-30 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines and methods for the treatment of periodontal disease using these and other immune response modifiers |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
US6921826B2 (en) | 2000-12-08 | 2005-07-26 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US6943255B2 (en) | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
US6953804B2 (en) | 2000-12-08 | 2005-10-11 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US7091214B2 (en) | 2002-12-20 | 2006-08-15 | 3M Innovative Properties Co. | Aryl substituted Imidazoquinolines |
WO2006107753A2 (fr) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines et analogues |
US7163947B2 (en) | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
US7179253B2 (en) | 2003-03-13 | 2007-02-20 | 3M Innovative Properties Company | Method of tattoo removal |
US7226928B2 (en) | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
US7299453B2 (en) | 2001-12-20 | 2007-11-20 | International Business Machines Corporation | Testing measurements |
US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
US7393859B2 (en) | 1999-06-10 | 2008-07-01 | Coley Pharmaceutical Group, Inc. | Amide substituted imidazoquinolines |
US7427629B2 (en) | 2002-08-15 | 2008-09-23 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
US7579359B2 (en) | 2004-09-02 | 2009-08-25 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
US7648997B2 (en) | 2003-08-12 | 2010-01-19 | Coley Pharmaceutical Group, Inc. | Hydroxylamine substituted imidazoquinolines |
US7696159B2 (en) | 2003-03-25 | 2010-04-13 | Graceway Pharmaceuticals, Llc | Treatment for basal cell carcinoma |
US7699057B2 (en) | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
US7884207B2 (en) | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US7939526B2 (en) | 2003-12-04 | 2011-05-10 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
US7968562B2 (en) | 2001-11-29 | 2011-06-28 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
US8143270B2 (en) | 2004-09-02 | 2012-03-27 | 3M Innovative Properties Company | 2-amino 1H-in-imidazo ring systems and methods |
US8188111B2 (en) | 2005-09-09 | 2012-05-29 | 3M Innovative Properties Company | Amide and carbamate derivatives of alkyl substituted N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods |
US8221771B2 (en) | 2003-08-05 | 2012-07-17 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
US8476292B2 (en) | 2005-09-09 | 2013-07-02 | 3M Innovative Properties Company | Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8778963B2 (en) | 2003-11-25 | 2014-07-15 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US8846710B2 (en) | 2005-02-23 | 2014-09-30 | 3M Innovative Properties Company | Method of preferentially inducing the biosynthesis of interferon |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US8961477B2 (en) | 2003-08-25 | 2015-02-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US9006264B2 (en) | 2004-06-18 | 2015-04-14 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US9107958B2 (en) | 2011-06-03 | 2015-08-18 | 3M Innovative Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
US9145410B2 (en) | 2003-10-03 | 2015-09-29 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
US9242980B2 (en) | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
US9546184B2 (en) | 2005-02-09 | 2017-01-17 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
US9801947B2 (en) | 2003-04-10 | 2017-10-31 | 3M Innovative Properties Company | Methods and compositions for enhancing immune response |
US10144735B2 (en) | 2006-12-22 | 2018-12-04 | 3M Innovative Properties Company | Immune response modifier compositions and methods |
US10472420B2 (en) | 2006-02-22 | 2019-11-12 | 3M Innovative Properties Company | Immune response modifier conjugates |
US11306083B2 (en) | 2017-12-20 | 2022-04-19 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
WO1998017279A1 (fr) * | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Composes modificateurs de la reponse immunitaire pour le traitement des maladies induites par les th2 ou associees |
WO1998024436A2 (fr) * | 1996-12-03 | 1998-06-11 | Minnesota Mining And Manufacturing Company | Formulations sous forme de gel pour l'administration locale de medicaments |
WO2000040228A2 (fr) * | 1999-01-08 | 2000-07-13 | 3M Innovative Properties Company | Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire |
-
2000
- 2000-11-06 JP JP2000337359A patent/JP2002145777A/ja active Pending
-
2001
- 2001-10-31 AU AU2002212695A patent/AU2002212695A1/en not_active Abandoned
- 2001-10-31 WO PCT/JP2001/009575 patent/WO2002036592A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389640A (en) * | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
WO1998017279A1 (fr) * | 1996-10-25 | 1998-04-30 | Minnesota Mining And Manufacturing Company | Composes modificateurs de la reponse immunitaire pour le traitement des maladies induites par les th2 ou associees |
WO1998024436A2 (fr) * | 1996-12-03 | 1998-06-11 | Minnesota Mining And Manufacturing Company | Formulations sous forme de gel pour l'administration locale de medicaments |
WO2000040228A2 (fr) * | 1999-01-08 | 2000-07-13 | 3M Innovative Properties Company | Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire |
Cited By (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624305B2 (en) | 1996-06-21 | 2003-09-23 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6534654B2 (en) | 1996-06-21 | 2003-03-18 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6897314B2 (en) | 1996-06-21 | 2005-05-24 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US7026482B2 (en) | 1996-06-21 | 2006-04-11 | Gerster John F | Process for preparing imidazoquinolinamines |
US6613902B2 (en) | 1996-06-21 | 2003-09-02 | 3M Innovative Properties Company | Process for preparing imidazoquinolinamines |
US6949646B2 (en) | 1997-12-11 | 2005-09-27 | 3M Innovative Properties Co. | Imidazonaphthyridines |
US6894165B2 (en) | 1997-12-11 | 2005-05-17 | 3M Innovative Properties Company | Imidazonaphthyridines |
US6747040B2 (en) | 1997-12-11 | 2004-06-08 | 3M Innovative Properties Company | Imidazonaphthyridines |
US7038051B2 (en) | 1997-12-11 | 2006-05-02 | 3M Innovative Properties Company | Imidazonaphthyridines |
US6797716B2 (en) | 1997-12-11 | 2004-09-28 | 3M Innovative Properties Company | Imidazonaphthyridines |
US7335773B2 (en) | 1997-12-11 | 2008-02-26 | Graceway Pharmaceuticals, Llc | Intermediates for imidazonaphthyridines |
US6699878B2 (en) | 1997-12-11 | 2004-03-02 | 3M Innovative Properties Company | Imidazonaphthyridines |
US7678918B2 (en) | 1997-12-11 | 2010-03-16 | 3M Innovative Properties Company | Intermediates for imidazonaphthyridines |
US6897221B2 (en) | 1999-06-10 | 2005-05-24 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6784188B2 (en) | 1999-06-10 | 2004-08-31 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6825350B2 (en) | 1999-06-10 | 2004-11-30 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines and methods for the treatment of periodontal disease using these and other immune response modifiers |
US7393859B2 (en) | 1999-06-10 | 2008-07-01 | Coley Pharmaceutical Group, Inc. | Amide substituted imidazoquinolines |
US7157453B2 (en) | 1999-06-10 | 2007-01-02 | 3M Innovation Properties Company | Urea substituted imidazoquinolines |
US6780873B2 (en) | 1999-06-10 | 2004-08-24 | 3M Innovative Properties Company | Urea substituted imidazoquinolines |
US6916925B1 (en) | 1999-11-05 | 2005-07-12 | 3M Innovative Properties Co. | Dye labeled imidazoquinoline compounds |
US7288550B2 (en) | 2000-12-08 | 2007-10-30 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6949649B2 (en) | 2000-12-08 | 2005-09-27 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US6545017B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6720334B2 (en) | 2000-12-08 | 2004-04-13 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6878719B2 (en) | 2000-12-08 | 2005-04-12 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6545016B1 (en) | 2000-12-08 | 2003-04-08 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6720422B2 (en) | 2000-12-08 | 2004-04-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6716988B2 (en) | 2000-12-08 | 2004-04-06 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6696465B2 (en) | 2000-12-08 | 2004-02-24 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6903113B2 (en) | 2000-12-08 | 2005-06-07 | 3M Innovative Properties Company | Urea substituted imidazopyridines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6921826B2 (en) | 2000-12-08 | 2005-07-26 | 3M Innovative Properties Co. | Thioether substituted imidazoquinolines |
US6720333B2 (en) | 2000-12-08 | 2004-04-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7132429B2 (en) | 2000-12-08 | 2006-11-07 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6953804B2 (en) | 2000-12-08 | 2005-10-11 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US6969722B2 (en) | 2000-12-08 | 2005-11-29 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US6989389B2 (en) | 2000-12-08 | 2006-01-24 | 3M Innovative Properties Co. | Aryl ether substituted imidazoquinolines |
US7214675B2 (en) | 2000-12-08 | 2007-05-08 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6525064B1 (en) | 2000-12-08 | 2003-02-25 | 3M Innovative Properties Company | Sulfonamido substituted imidazopyridines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US7078523B2 (en) | 2000-12-08 | 2006-07-18 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US7276515B2 (en) | 2000-12-08 | 2007-10-02 | Coley Pharmaceutical Group, Inc. | Thioether substituted imidazoquinolines |
US7098221B2 (en) | 2000-12-08 | 2006-08-29 | 3M Innovative Properties Company | Amide substituted imidazopyridines |
US7115622B2 (en) | 2000-12-08 | 2006-10-03 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US7226928B2 (en) | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
US7968562B2 (en) | 2001-11-29 | 2011-06-28 | 3M Innovative Properties Company | Pharmaceutical formulations comprising an immune response modifier |
US7299453B2 (en) | 2001-12-20 | 2007-11-20 | International Business Machines Corporation | Testing measurements |
US6924293B2 (en) | 2001-12-21 | 2005-08-02 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6888000B2 (en) | 2001-12-21 | 2005-05-03 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US7199131B2 (en) | 2001-12-21 | 2007-04-03 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6797718B2 (en) | 2002-06-07 | 2004-09-28 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US7220758B2 (en) | 2002-06-07 | 2007-05-22 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US7125890B2 (en) | 2002-06-07 | 2006-10-24 | 3M Innovative Properties Company | Ether substituted imidazopyridines |
US7427629B2 (en) | 2002-08-15 | 2008-09-23 | 3M Innovative Properties Company | Immunostimulatory compositions and methods of stimulating an immune response |
US6818650B2 (en) | 2002-09-26 | 2004-11-16 | 3M Innovative Properties Company | 1H-imidazo dimers |
US7112677B2 (en) | 2002-09-26 | 2006-09-26 | 3M Innovative Properties Company | 1H-imidazo dimers |
US7598382B2 (en) | 2002-12-20 | 2009-10-06 | Coley Pharmaceutical Group, Inc. | Aryl substituted imidazoquinolines |
US7091214B2 (en) | 2002-12-20 | 2006-08-15 | 3M Innovative Properties Co. | Aryl substituted Imidazoquinolines |
US10105426B2 (en) | 2002-12-30 | 2018-10-23 | Trustees Of Dartmouth College | Immunostimulatory combinations |
US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
US8329197B2 (en) | 2002-12-30 | 2012-12-11 | 3M Innovative Properties Company | Ex vivo uses of immunostimulatory combinations |
US7375180B2 (en) | 2003-02-13 | 2008-05-20 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and Toll-like receptor 8 |
US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
US8110582B2 (en) | 2003-03-04 | 2012-02-07 | 3M Innovative Properties Company | Prophylactic treatment of UV-induced epidermal neoplasia |
US7163947B2 (en) | 2003-03-07 | 2007-01-16 | 3M Innovative Properties Company | 1-Amino 1H-imidazoquinolines |
US8426457B2 (en) | 2003-03-13 | 2013-04-23 | Medicis Pharmaceutical Corporation | Methods of improving skin quality |
US7179253B2 (en) | 2003-03-13 | 2007-02-20 | 3M Innovative Properties Company | Method of tattoo removal |
US7699057B2 (en) | 2003-03-13 | 2010-04-20 | 3M Innovative Properties Company | Methods for treating skin lesions |
US7696159B2 (en) | 2003-03-25 | 2010-04-13 | Graceway Pharmaceuticals, Llc | Treatment for basal cell carcinoma |
US8835394B2 (en) | 2003-03-25 | 2014-09-16 | Medicis Pharmaceutical Corporation | Treatment for basal cell carcinoma |
US9801947B2 (en) | 2003-04-10 | 2017-10-31 | 3M Innovative Properties Company | Methods and compositions for enhancing immune response |
US7923560B2 (en) | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US7038053B2 (en) | 2003-06-06 | 2006-05-02 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
US6943255B2 (en) | 2003-06-06 | 2005-09-13 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
US8221771B2 (en) | 2003-08-05 | 2012-07-17 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
US7648997B2 (en) | 2003-08-12 | 2010-01-19 | Coley Pharmaceutical Group, Inc. | Hydroxylamine substituted imidazoquinolines |
US8961477B2 (en) | 2003-08-25 | 2015-02-24 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
US9145410B2 (en) | 2003-10-03 | 2015-09-29 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
US9365567B2 (en) | 2003-10-03 | 2016-06-14 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US7879849B2 (en) | 2003-10-03 | 2011-02-01 | 3M Innovative Properties Company | Pyrazolopyridines and analogs thereof |
US9856254B2 (en) | 2003-10-03 | 2018-01-02 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US8871782B2 (en) | 2003-10-03 | 2014-10-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
US20140194628A1 (en) * | 2003-11-25 | 2014-07-10 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8778963B2 (en) | 2003-11-25 | 2014-07-15 | 3M Innovative Properties Company | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US9328110B2 (en) * | 2003-11-25 | 2016-05-03 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US9765071B2 (en) | 2003-11-25 | 2017-09-19 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8691837B2 (en) | 2003-11-25 | 2014-04-08 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8940755B2 (en) | 2003-12-02 | 2015-01-27 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US7939526B2 (en) | 2003-12-04 | 2011-05-10 | 3M Innovative Properties Company | Sulfone substituted imidazo ring ethers |
US7884207B2 (en) | 2004-06-18 | 2011-02-08 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US9006264B2 (en) | 2004-06-18 | 2015-04-14 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US9550773B2 (en) | 2004-06-18 | 2017-01-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US9938275B2 (en) | 2004-06-18 | 2018-04-10 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
US7579359B2 (en) | 2004-09-02 | 2009-08-25 | 3M Innovative Properties Company | 1-alkoxy 1H-imidazo ring systems and methods |
US8143270B2 (en) | 2004-09-02 | 2012-03-27 | 3M Innovative Properties Company | 2-amino 1H-in-imidazo ring systems and methods |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US10071156B2 (en) | 2005-02-04 | 2018-09-11 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US9546184B2 (en) | 2005-02-09 | 2017-01-17 | 3M Innovative Properties Company | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines |
US8846710B2 (en) | 2005-02-23 | 2014-09-30 | 3M Innovative Properties Company | Method of preferentially inducing the biosynthesis of interferon |
WO2006107753A2 (fr) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines et analogues |
US8476292B2 (en) | 2005-09-09 | 2013-07-02 | 3M Innovative Properties Company | Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods |
US8188111B2 (en) | 2005-09-09 | 2012-05-29 | 3M Innovative Properties Company | Amide and carbamate derivatives of alkyl substituted N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods |
US10472420B2 (en) | 2006-02-22 | 2019-11-12 | 3M Innovative Properties Company | Immune response modifier conjugates |
US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
US10144735B2 (en) | 2006-12-22 | 2018-12-04 | 3M Innovative Properties Company | Immune response modifier compositions and methods |
US10383938B2 (en) | 2010-08-17 | 2019-08-20 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US11524071B2 (en) | 2010-08-17 | 2022-12-13 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US9795669B2 (en) | 2010-08-17 | 2017-10-24 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US9242980B2 (en) | 2010-08-17 | 2016-01-26 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US10821176B2 (en) | 2010-08-17 | 2020-11-03 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US10052380B2 (en) | 2010-08-17 | 2018-08-21 | 3M Innovative Properties Company | Lipidated immune response modifier compound compositions, formulations, and methods |
US9107958B2 (en) | 2011-06-03 | 2015-08-18 | 3M Innovative Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
US10406142B2 (en) | 2011-06-03 | 2019-09-10 | 3M Lnnovative Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
US9902724B2 (en) | 2011-06-03 | 2018-02-27 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
US10723731B2 (en) | 2011-06-03 | 2020-07-28 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
US9585968B2 (en) | 2011-06-03 | 2017-03-07 | 3M Innovative Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
US11306083B2 (en) | 2017-12-20 | 2022-04-19 | 3M Innovative Properties Company | Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier |
Also Published As
Publication number | Publication date |
---|---|
JP2002145777A (ja) | 2002-05-22 |
AU2002212695A1 (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002036592A1 (fr) | Remedes aux maladies causees par l'acide arachidonique | |
JP7085073B2 (ja) | 炎症性皮膚疾患を処置するための局所組成物及び方法 | |
KR101699572B1 (ko) | 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 | |
CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
TW201713334A (zh) | 小蘗鹼製劑之治療用途 | |
WO2020190072A1 (fr) | Composition favorisant la cicatrisation des plaies cutanées ou la régénération de la peau, contenant du (r)-ginsénoside rg3 en tant que principe actif | |
KR20070059079A (ko) | 경피 페로스피론 투여용 의약적 조성물 | |
US5556871A (en) | Method for treating epithelial precancerous lesions with topical inidazoles | |
WO2020004404A1 (fr) | INHIBITEUR DE L'IL-1β | |
US9073884B2 (en) | Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them | |
CN114366732B (zh) | 泰妙菌素在制备用于治疗银屑病的药物中的应用 | |
KR20050102663A (ko) | 치질환 치료제 | |
WO2023035200A1 (fr) | Application de pentafluorine dans la préparation d'un médicament pour le traitement du cancer de l'endomètre | |
JP7396585B2 (ja) | Tslp遺伝子発現抑制用、il-33遺伝子発現抑制用、又はフィラグリン産生促進用組成物 | |
JPH01279818A (ja) | 白髪黒化剤 | |
JPH11322603A (ja) | 抗腫瘍作用増強剤 | |
JP2001163783A (ja) | 皮膚疾患治療用外用剤 | |
CA2575842A1 (fr) | Composition contenant un derive de la thio-uree destinee a prevenir ou a traiter des maladies de la peau prurigineuses ou irritantes | |
TW202339711A (zh) | 預防或治療心血管疾病的高穿透性的阿司匹靈和其他非類固醇抗發炎藥的前藥 | |
WO2024078468A1 (fr) | Utilisation d'un dérivé de stilbène dans la prévention et/ou le traitement d'ulcères | |
CN117137916A (zh) | 盐酸去亚甲基小檗碱在制备预防或治疗银屑病药物的应用 | |
CN114848672A (zh) | 富勒烯组合物在制备治疗炎症性黏膜疾病的药物中的应用 | |
CN114917214A (zh) | Trpm2抑制剂在制备治疗和/或预防肝癌的药物中的应用 | |
CN115381820A (zh) | 盐酸去亚甲基四氢小檗碱在制备治疗溃疡性结肠炎药物中的应用 | |
WO2019008472A1 (fr) | Compositions pharmaceutiques de lignocaïne hcl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |